Eng Sze Wei, Muniandy Vilassini, Punniamoorthy Lohshinni, Tew Hui Xian, Norazmi Mohd Nor, Ravichandran Manickam, Lee Su Yin
Faculty of Applied Sciences, AIMST University, Kedah, Malaysia.
Centre of Excellence for Vaccine Development (CoEVD), Faculty of Applied Science, AIMST University, Kedah, Malaysia.
Malays J Med Sci. 2024 Dec;31(6):6-20. doi: 10.21315/mjms2024.31.6.2. Epub 2024 Dec 31.
DNA vaccines are third-generation vaccines composed of plasmids that encode vaccine antigens. Their advantages include fast development, safety, stability, and cost effectiveness, which make them an attractive vaccine platform for genetic and infectious diseases. However, the low transfection efficiency of DNA vaccines results in poor performance in both larger animals and humans, thereby limiting their clinical use. To overcome this issue, live attenuated bacterial vector (LABV) has been proposed as a DNA delivery vehicle. LABV is known to improve DNA vaccine transfection efficiency, thus enhancing the immune response. This article highlights recent advancements in the development of LABV DNA vaccines, the design of shuttle plasmids and adjuvants, and the potential applications of LABV candidates.
DNA疫苗是由编码疫苗抗原的质粒组成的第三代疫苗。它们的优点包括开发速度快、安全性高、稳定性好以及成本效益高,这些特点使其成为用于遗传疾病和传染病的极具吸引力的疫苗平台。然而,DNA疫苗的低转染效率导致其在大型动物和人类中的效果不佳,从而限制了它们的临床应用。为了克服这一问题,减毒活细菌载体(LABV)已被提议作为一种DNA递送载体。已知LABV可提高DNA疫苗的转染效率,从而增强免疫反应。本文重点介绍了LABV DNA疫苗开发、穿梭质粒和佐剂设计以及LABV候选物潜在应用方面的最新进展。